Concepedia

Michael Roehrle

MR

Statistics

Publications

3

Citations

360

H-Index

3

Active since

2005

Affiliations

Basilea Pharmaceutica (Switzerland)(Current)

Neu-Ulm University of Applied Sciences

Michael Roehrle is an author at Basilea Pharmaceutica (Switzerland) specializing in clinical pharmacology, pharmacology, and antifungal pharmacology.

Publications per year

2005–2019

3

Publications

3

Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers

Anne Schmitt‐Hoffmann, Brigitte Roos, M. Heep et al. · Antimicrobial Agents and Chemotherapy · 2005 · 169 citations

, , +13

Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers

Anne Schmitt‐Hoffmann, Brigitte Roos, J. Maares et al. · Antimicrobial Agents and Chemotherapy · 2005 · 139 citations

, , +16

Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease

Lutz Frölich, Glen Wunderlich, Claus Thamer et al. · Alzheimer s Research & Therapy · 2019 · 52 citations · Full text

, , +17

1–3 of 3